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Abstract Treatment of jugulotympanic paragangliomas
(JTPGLs) remains challenging with no clear guidelines for
management or follow-up. The aim of this retrospective
case-note study was to assess long-term results of opera-
tively and conservatively managed JTPGLs between years
1974–2013. A total of 36 patients with JTPGLs were
identified. Clinical characteristics and management out-
comes of patients were reviewed. Data were extracted on
demographics, symptoms, timing of diagnosis, tumor
location and size, embolization, and management, includ-
ing pre- and post-operative imaging, analysis of operative
techniques, and follow-up. Pulsatile tinnitus and hearing
loss were the most common presenting symptoms. Thirty-
four (94 %) patients were treated with primary surgical
therapy and two (6 %) with radiotherapy. The surgical
approaches included endaural approach for Fisch Class A
tumors and a variety of approaches for Fisch Class B-D
tumors with an increasing predilection for function-pre-
serving surgery. Eight (24 %) patients received subtotal
resection. Five (15 %) patients had a local recurrence
within 10 years after primary surgery. Two (6 %) patients
suffered a permanent cranial nerve (CN) deficit after pri-
mary surgery. We advocate radical surgery when tumor
resection is possible without compromising CNs. Function-
preserving surgery with at least a 10-year follow-up for
Fisch Class B–D tumors should be considered if CNs are in
danger.
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Introduction
Paragangliomas (PGLs) are highly vascular and largely
benign tumors of neuroendocrine origin that exhibit a
frequency of 1:300,000 in the head and neck area [1].
Head and neck PGLs (HNPGLs) occur in four main areas
of the head and neck as tympanic, jugular, carotid body,
and vagal PGLs that display their symptoms mainly by
pressure effect on the nearby cranial nerves (CNs) [2, 3].
PGLs are diagnosed as malignant if distant metastasis
takes place; this occurs in less than 10 % of HNPGLs
[3–5].
B-mode and color duplex sonography, magnetic reso-
nance imaging (MRI), and computed tomography (CT)
scanning are the most common imaging techniques utilized
to visualize HNPGLs. Surgery (total or subtotal resection),
primary or post-operative stereotactic radiotherapy (RT),
and conservative wait-and-scan strategy are examples of
possible management trends for selected HNPGLs [6].
Fisch classification (Table 1) is mainly used for the pre-
operative treatment planning of jugulotympanic paragan-
gliomas (JTPGLs) [7, 8]. An individual patient’s age,
comorbidity, size and extension of the tumor, predicted
tumor growth, and pre-operative CN function influence
potential treatment approaches.
The purpose of this study was to record the incidence of
JTPGLs treated between 1974 and 2013 at Helsinki
University Hospital (HUH), with a referral area that cur-
rently covers a population of approximately 1.9 million
people in Finland. The emphasis was on the operative
techniques used, their complications, and how they related
to patients’ post-operative morbidity.
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Methods
We retrospectively reviewed the clinico-radio-pathological
records of all patients with a histologically confirmed
JTPGL who were managed with curative intent at the HUH
during a 40-year period between 1974 and 2013.
Data on age, sex, symptoms, timing of diagnosis, tumor
location and quantity, embolization, Charlson’s Comor-
bidity Index (CCI) [9], management, including pre- and
post-operative imaging, and detailed analysis of operative
steps, as well as follow-up were recorded. The JTPGLs
were categorized according to the modified Fisch classifi-
cation [8] and pre- and post-operative facial nerve function
according to the House–Brackmann (H-B) scale [10].
All Fisch Class A tumors as well as the early Class B
tumors were operated on by an otorhinolaryngologist. Since
the 1990s, Fisch Class B–D tumors were treated at a neuro-
surgical department with access to a neurosurgical intensive
care unit. These later tumors were operated on by a skull base
surgeon/otologist unless there was intracranial extension
that necessitated collaboration with a neurosurgeon.
Statistical analyses were carried out using a computer-
ized software package (SPSS, version 22.0, Chicago, IL,
USA). Institutional research permission was granted for the
study protocol (Section 54, 11.03.2014). The study was




A total of 36 patients with tympanic, jugular, or jugulo-
tympanic PGLs were treated during the study period. There
were 10 (28 %) men and 26 (72 %) women with an aver-
age age of 55 years (range 24–73). Seven (19 %) patients
were considered to be elderly ([65 years of age). At the
time of diagnosis, the patients had a median CCI of 0
(range 0–3) with 20 patients having no past medical history
to report. The population-based annual incidence of
JTPGLs was 0.5 cases per 1,000,000 inhabitants. Genetic
testing for SDHx mutations was not routinely performed.
Presenting symptoms
The main presenting symptoms were pulsatile tinnitus and
hearing loss. Seven (19 %) patients presented with 1 or 2
simultaneous cranial neuropathies in CNs VII, X, XI, and
XII. The presenting symptoms are outlined in Fig. 1.
Pre-treatment radiological imaging
All patients had radiological imaging before treatment. The
imaging modalities included CT in 12 (33 %), MRI in 3
(8 %), as well as a combination of: CT ? MRI in 11
(31 %), CT ? MRI ? MRA in 4 (11 %), CT ? MRA in 2
(6 %), CT ? temporal bone radiograph ? carotid angiog-
raphy in 1 (3 %), temporal bone radiograph in 1 (3 %), and
CT ? temporal bone radiograph ? carotid angiography in
2 (6 %).
Location of tumors and Fisch classification
Eighteen (50 %) tumors were located in the tympanic area,
11 (31 %) in the jugular area, while 7 (19 %) tumors were
considered to be jugulotympanic. Figure 2 shows tumors as
per the modified Fisch classification. Urinary metanephri-
nes and plasma chromogranin A were measured in 5
Table 1 Classification of JTPGLs according to the modified Fisch classification [8]
Class Location and extension of PGL
A1 Tumors completely visible on otoscopic examination
A2 Tumor margins are not visible on otoscopy. Tumors may extend anteriorly to the Eustachian tube and/or to the posterior mesotympanum
B1 Tumors confined to the middle ear cleft with extension to the hypotympanum
B2 Tumors involving the middle ear cleft with extension to the hypotympanum and the mastoid
B3 Tumors confined to the tympanomastoid compartment with erosion of the carotid canal
C1 Tumors with limited involvement of the vertical portion of the carotid canal
C2 Tumors invading the vertical portion of the carotid canal
C3 Tumors with invasion of the horizontal portion of the carotid canal
C4 Tumors reaching the anterior foramen lacerum
De1/2 PGLs with intracranial but extradural extension [De, displacement of the dura\2 cm (1),[2 cm (2)]
Di1/2/3 PGLs with intracranial and intradural extension (Di, depth of invasion into the posterior cranial canal\2 cm (1), 2–4 cm (2),[4 cm
(inoperable)
Ve Tumors involving the extradural vertebral artery
Vi Tumors involving the intradural vertebral artery
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(14 %) patients without a set protocol: none presented
hormonal activity.
Pre-operative embolization and biopsies
Pre-operative embolization utilizing digital subtraction
angiography (DSA) was used in large Fisch Class B-D
tumors. Embolization, used in our clinic since 1996, was
successful in eight (22 %) cases and, furthermore,
attempted in two, but proved difficult due to proximal
anatomy of the neck vessels or the presence of multiple
feeding vessels in critical areas. There were no complica-
tions related to this procedure. In seven (19 %) patients,
pre-operative biopsies of the tumor were taken.
Operative and conservative management
Thirty-four (94 %) patients were managed with primary
surgical therapy, while 2 (6 %) patients received RT as
their primary treatment. RT was chosen because of patient
preference (Fisch Class C3) or an inoperable tumor (Fisch
Class Di3). For both patients, 50 Gy of radiation was
given stereotactically in 2 Gy fractions. The sizes of the
PGLs ranged between 2 and 13 mm for Class A1–B3
tumors and between 2 and 35 mm for Class C1–De2
tumors.
Surgical approaches
The surgical approaches included endaural approach for
Fisch Class A tumors. In the 1970s and 1980s, Fisch Class
B-D tumors were resected via variable surgical approaches,
whereas between the 1990s and the second half of the
2000s, the approach was via infratemporal fossa. The latter
technique included transposition of the facial nerve, liga-
tion of the sigmoid sinus, and excision of the cranial end of
the jugular vein. In the last 5–10 years, facial nerve has
been kept in its bony recess, the internal jugular vein
ligated, and the cranial end of the sigmoid sinus packed to
preserve function of the CNs. Whenever possible, the
middle ear was kept intact. Table 2 outlines the intraop-
erative steps taken for Class B1–De2 tumors and the
approaches used. All infratemporal fossa approach A and B
tumors received 1 g intravenous vancomycin periopera-
tively. Facial nerve monitoring was routinely used in all
skull-base operations.
Intraoperative blood pressure, blood loss,
and complications
A sustained intraoperative blood pressure (BP) rise of
60–130 mmHg was detected in 4 (11 %) patients. Twelve
(33 %) patients had sustained 5–5200 mL of intraoperative
bleeding. Six of the 12 patients had undergone pre-opera-
tive embolization; embolization was, furthermore,
attempted in 1 patient. In 2 patients (Fisch Class B3 and De1
tumors), a 1–3 L blood loss was noted, while in another (a
Fisch Class De2 tumor), an excess of 5 L of blood was lost
intraoperatively. All 3 patients had been embolized pre-
operatively and were the only ones to receive blood
transfusion after primary surgery. Further intraoperative
complications included a small cerebrospinal fluid leak in 1
patient.
Follow-up and outcome
The first post-operative follow-up appointment took rou-
tinely place between 1 and 2 months, the second between 2
and 4 months, and the third between 10 and 12 months.
The follow-up included clinical examination and radio-
logical imaging in selected cases. After primary surgery, 8
patients were evaluated by CT, 3 by MRI, and 6 by
CT ? MRI scanning. There was no departmental guideline
for the length of routine follow-up. The mean total follow-
Fig. 1 Pre-treatment presenting symptoms in 36 patients with a
JTPGL
Fig. 2 Fisch classification in 36 patients with a JTPGL
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up time was 6.1 years (range 0.5–37). Even if the follow-
up period tended to be shorter for Fisch Class A and B
tumors, its length depended on intraoperative findings,
post-operative examination, and radiological findings, as
well as patients’ complaints.
The first of the two patients who received RT (Fisch
Class C3) did not want further follow-up. Her pre-treat-
ment complaints included CN X and XII palsies. One
MRI was taken at 2-year post-RT, which showed no new
growth of the tumor. The second patient treated with RT
for her Fisch Class Di3 tumor had a 6-year history of
unilateral deafness before the extensive JTPGL was dis-
covered due to a new CN VII palsy. Before RT, the CN
VII was Grade I–II. Immediately post-RT, the patient
suffered new CN XII as well as Grade IV CN VII palsies.
The patient was followed-up for 4 years post-RT and at
the last appointment had a Grade II CN VII palsy and CN
XII palsy with normal swallowing function. Serial CT
scans showed no new growth in the tumor during the
follow-up time.
One patient (Fisch Class De2) died of stroke within 24 h
following surgery due to bleeding obstructing the fourth
ventricle. None of the other patients died as a direct or
indirect consequence of a JTPGL.
Short- and long-term post-treatment cranial nerve
deficits and secondary treatment approaches
Table 3 highlights the short- and long-term post-operative
CN deficits, and residual and recurrent tumors, as well as
the secondary treatment approaches. In eight (24 %) cases,
a residual was either left in situ perioperatively (subtotal
resection) or found within a 6-month post-operative period.
During follow-up, 5 (15 %) patients had a local recurrence.
One patient (patient 35, Table 3) had a second recurrence
14 years after primary surgery. Four out of five pre-oper-
atively paralyzed CNs recovered their function post-oper-
atively. Four (11 %) surgically managed patients suffered a
new long-term CN palsy after primary surgery. Two (6 %)
of the four patients were left with a permanent CN deficit.
Treatment modalities of short- and long-term compli-
cations after primary surgery or secondary surgery/RT are
presented in Table 4. Secondary RT entailed giving 50 Gy
of radiation in 2 Gy fractions stereotactically with the
exception of 2 early patients (patients 33 and 35) who
received external beam RT for tumor recurrence. Patient 21
sustained a new CN VII palsy 2 years after secondary RT.
At the time, no new growth was seen in the tumor and the
deficit was thought to result from a combination of the























–a B1 EA (R) Variable 4
20 B1 RA (R) 2000 4
9 B1 ITFB (R) 2005 4
33 B2 TM (I) 1986 4
24 B2 TM (R) 1998 4
2 B2 ITFA (I) 2009 4 4 4 4 4
15 B3 ITFB (R) 2004 4 4 4 4 4
31 C1 ITFB (R) 1990 4 4 4 4 4 4
22 C1 ITFA (I) 2000 4 4 4 4 4 4
17 C2 ITFA (I) 2003 4 4
19 C2 RS (R) 2003 4 4 4 4
28 C3 PS (R) 1993 4 4 4 4 4
10 C3 ITFA (I) 2003 4
8 C3 ITFB (S) 2006 4 4 4 4 4 4
1 C3 ITFB (S) 2010 4 4 4 4 4
23 De1 ITFB (I) 1996 4 4
21 De1 PFA (R) 2000 4 4 4
4 De1 RS (I) 2008 4 4 4 4 4 4
11 De2 ITFB (S) 2005 4 4 4 4 4 4
pt patient, class classification, IJV internal jugular vein, SS sigmoid sinus, CN VII facial nerve, CN IX–XII glossopharyngeal–hypoglossal nerves,
ICA internal carotid artery, VA vertebral artery, trans transposition, EA endaural, RA retroauricular, RS retrosigmoidal, ITFA infratemporal fossa
type A, ITFB infratemporal fossa type B, TM tympanomastoidectomy, PS petrosectomy, PFA posterior fossa approach, R radical, S sparing
(planned), I incomplete (unplanned)
a Altogether 7 patients
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tumor and scars—or to be idiopathic. Patient 23 underwent
altogether five operations during the study period, but some
PGL still remained.
Discussion
Treatment of JTPGLs is challenging, possible post-opera-
tive morbidity is considerable, and no general guidelines for
treatment or follow-up are available. Our institution’s
strategy includes radical surgery when complete tumor
resection is possible. If CNs are in danger, we advocate
function-preserving surgery. While subtotal tumor resection
may help relieve pressure symptoms in large inoperable
tumors, primary RT is another viable alternative to control
local tumor growth in complex JTPGLs. This retrospective
study reviews the results of our strategy with the aim of
comparing them with the results in the current literature.
This study provides epidemiological, population-based
data on JTPGLs managed at the HUH district during the
past 40 years with a catchment area of 1.9 million people,
which is approximately a third of Finland’s population. The
main strength of this study is the completeness of the
patient data; no patient was lost to follow-up. Despite the
extent of the study setting, the patient cohort remains
comparatively small.
A high level of tumor control combined with minimal
morbidity from CN VII–XII deficits and preservation of
hearing are the main goals of JTPGL treatment. Ku¨nzel
et al. recommend primary surgical resection for young
patients with unilateral tumors and evident CN pareses [6].
When there is evidence of pre-operative lower CN dys-
function, Ahmad et al. [11] endorse total resection of the
involved CNs followed-up by the rehabilitative surgical
procedures in case poorly compensated CN dysfunction
persists after 6 months [11, 12]. For older patients whose
Table 3 Pre- and post-operative cranial nerve defects, JTPGL recurrences, and secondary treatment modalities. Short-term (ST) =\6 months,


























35a B1 37 1977 VIII (mixed) EA (R) 4 (3) 4 (3) 4 (14)
27 B1 60 1994 EA (R) 4 (10) 4 (10)
7 B1 58 2006 VIII (mixed) EA (R) VII
33 B2 67 1986 TM (I) 4 (0) 4 (0) 4 (0)
2 B2 66 2009 ITFA (I) VII, XII
15 B3 60 2004 VIII (mixed) ITFB (R) 4 (4) 4 (8)
31 C1 52 1990 VIII (mixed) ITFB (R) VII, IX–XI XI
22b C1 46 2000 X, XII ITFA (I) VI, VII, XI 4 (0)
17 C2 57 2003 ITFA (I) 4 (0) 4 (9)
19 C2 56 2003 VIII (SNHL) RS (R) VII, X VII 4 (2) 4 (2)
28 C3 50 1993 VIII (SNHL) PS (R) IX–XI X
10 C3 53 2003 VIII (mixed) ITFA (I) 4 (0) 4 (2) 4 (5)
8 C3 34 2006 X, XI ITFB (S) IX, X, XII 4 (0) 4 (0)
1 C3 57 2010 VIII
(mixed),
XI
ITFB (S) VII 4 (2) 4 (2)
23c De1 47 1996 ITFB (I) 4 (0) 4 (2)
21 De1 68 2000 X PFA (R) VIII–XI X 4 (0) 4 (4)
4 De1 53 2008 RS (I) VIII 4 (0) 4 (4)
11d De2 59 2005 X, XII ITFB (S)
pt patient, class classification, RS retrosigmoidal, ITFA infratemporal fossa type A, ITFB infratemporal fossa type B, RA retroauricular, TM
tympanomastoidectomy, PS petrosectomy, PFA posterior fossa approach, EA endaural, R radical, S sparing (planned), I incomplete, (unplanned),
RT radiotherapy, CN cranial nerve, SNHL sensorineural hearing loss
a Second recurrence 14 years after primary surgery
b Intraoperatively some tumor left on dura; not seen in post-operative imaging
c Altogether 5 operations: incomplete excision
d Death\24 h post-op (stroke)
e Years after primary surgery
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CN function is normal and hearing satisfactory, subtotal
tumor resection may suffice [12]. Willen et al. advocate
limited middle ear/mastoid tumor resection followed by
post-operative RT in elderly patients to minimize treat-
ment-related morbidity, to reduce pulsatile tinnitus, and to
improve residual hearing [13]. Cosetti et al. further support
conservative surgical excision with vigilant long-term
monitoring in patients with advanced age [14]. According
to a meta-analysis by Ivan et al., patients undergoing
stereotactic radiosurgery (SRS) alone experienced the
lowest rates of recurrence where the incidence of CN IX–
XI deficits was higher in the gross-total resection group
[15]. Forbes et al. note that while radiosurgery should be
considered a practicable approach in the primary treatment
of JTPGLs, long-term data are lacking [16]. A review by
Suarez et al. comparing the efficacy and safety of surgery,
external beam radiotherapy (EBRT), and SRS for jugular
PGLs noted that, compared to surgery, EBRT and SRS
offer lower risks of morbidity and similar chance of tumor
control [17].
At our institution, patients have been offered surgical
resection as the primary treatment without a set guideline;
in the present cohort, only two received RT due to personal
choice or an inoperable tumor. Seven patients were elderly
and six of them underwent surgical treatment between the
years 1986–2013. Five of the six patients had normal CN
function pre-operatively with one patient presenting with a
CN X palsy that persisted post-operatively. While none
suffered a new long-term CN dysfunction post-operatively,
one patient had a post-operative TMP that was conse-
quently repaired.
In the whole cohort, altogether 2 (6 %) patients suffered
a new permanent CN palsy after primary surgery. Sanna
et al. report a new post-operative lower CN deficit rate of
54 % after primary surgery in a cohort of 122 class C and
D JTPGLs [18]. The pre-operative CN deficit rate was
44 % in their cohort and none of the patients recovered
function of the pre-operatively paralyzed CNs. The repor-
ted incidences of new post-operative lower CN deficits
after JTPGL surgery, between 5 and 59 % across the lit-
erature in the past 20 years, were also revisited [18]. A
recent Spanish study further reports a 45.5 % post-opera-
tive CN deficit in JTPGLs overall, rising to 100 % in
tumors with intradural extension [19]. The noticeably low
Table 4 Short- (ST) and long-term (LT) complications and their treatment after primary and secondary surgery (age = at the time of surgery)
Pt Fisch
class





ST complication LT complication Treatment/other
26 A1 68 1995 4 TMP Tympanoplasty
32 A2 33 1989 4 TMP Myringoplasty
35 B1 40 1980 4 CN VII palsy (for
5 months)
Deafness of the treated
ear
9 B1 59 2005 4 TMP Tympanoplasty
6 B1 59 2006 4 TMP Pt refused operative treatment
31 C1 52 1990 4 CN XI palsy Early retirement due to CN XI palsy
19 C2 56 2003 4 CN VII palsy Permanent grade II (H-B) CN VII palsy
(minor asymmetry of one corner of
mouth) managed conservatively
28 C3 50 1993 4 CN X palsy Thyroplasty
10 C3 55 2005 4 CN X palsy, TMP Injection laryngoplasty, tympanoplasty
8 C3 34 2006 4 CN X palsy Thyroplasty
23 De1
a 47, 49 1996,
1998




Gold weight to upper eyelid (for CN VII
palsy), grafting of ICA (for ICA
pseudoaneurysm), CSF fistula repair
(gastrostomy, spinal drain, speech
therapy also in 1998)
21 De1 68, 74 2000,
2006
4 4* Tracheostomy (post-
primary surgery)
CN X palsy (post-
primary surgery);
CN VII palsy
(2 years after RT)
CN X palsy recovered to pre-operative
state over the years without
intervention; facial reanimation for
CN VII palsy
4 De1 57 2012 4 Pharyngeal constrictor
muscle dysfunction
Conservative treatment
pt patient, prim primary, class classification, RT radiotherapy, ST short-term, LT long-term, CN VII facial nerve, CN X vagus nerve, CN XI
accessory nerve, TMP tympanic membrane perforation, H-B House–Brackmann scale, ICA internal carotid artery, CSF cerebrospinal fluid
a Altogether 5 operations: 2 in 1996, 3 in 1998 (initially wrongly diagnosed as a meningioma)
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incidence of post-operative CN deficits in our cohort can be
explained by the avoidance of CN sacrifice in favor of
subtotal tumor resection. While supporting function-pre-
serving surgery, we stress the importance of long-term
follow-up as tumor residuals and recurrences were not
uncommon in our cohort. A recent study reports that if
more than 80 % of the pre-operative tumor volume is
resected, the residual tumor seems less likely to grow [20].
Subtotal tumor resection in large inoperable tumors is also
often enough to abolish patients’ distressing symptoms,
including pulsatile tinnitus, pressure in the ear, and head-
ache. Subtotal tumor resection may also improve patients’
residual hearing by lessening conductive hearing loss.
Pre-operative embolization of JTPGLs may reduce
intraoperative blood loss and operative duration and should
be carried out if possible [21, 22]. At our institution, this
technique has been utilized only after 1996 and thus, in a
fifth of cases in the present cohort. While embolization did
not drastically affect macroscopic intraoperative blood
loss, the reduction in intraoperative microscopic bleeding
in embolized patients greatly improved operative visibility.
If surgery is chosen as the treatment modality of choice,
Boedeker suggests transmeatal approach or an approach
via mastoidectomy for Fisch Class A and B tumors [23]. In
some Class B JTPGLs, juxtacondylar approach is recom-
mended. In our cohort, all Fisch Class A tumors were
resected via an endaural approach, while the approach
varied for Class B tumors. In the literature, Class C and D
tumors are usually resected via an infratemporal approach,
although juxtacondylar approach may be necessary for
Class C1, C2, and Dei1/2 tumors [23, 24]. For Class Di1/2
tumors that extend intradurally, a multidisciplinary proce-
dure involving neurosurgeons is necessary. Fisch Class Di3
tumors are primarily treated with palliative RT. In our
cohort, Class C tumors were mainly resected via an
infratemporal approach, whilst for Class De1/2 tumors, the
approach again varied broadly. The incidence of post-op-
erative CN palsies and other complications in patients with
intracranial, but extradural extension (De1/2) was no higher
than in those with less extensive tumors.
Surgery on tympanic PGLs will directly improve the
clinical situation of the patient with minimal risks of CN
damage. Thus, surgical indications are not the same for
tympanic, as they are for more wide-spread JTPGLs. It is
technically possible to operatively remove the tumor rad-
ically even in the most wide-spread intracranially invading
tumors. However, even with the most advanced surgical
techniques, the risks of permanent deficits of CNs VII and
IX–XI are very high. The rates of CN deficits following
aggressive surgery are described in publications of the
world’s most operatively oriented clinics [18]. With Fisch
Class A and B tumors, radical operative eradication of the
tumor is the preferred choice. If the tumor is larger and
invading into the CNs IX–XI, the risk–benefit ratio of the
radical operation should be profoundly discussed with the
patient and the other treatment options (subtotal resection
and post-operative radiotherapy if needed; radiotherapy
alone or, and in certain cases, a wait-and-scan policy)
considered.
While the surgical techniques have remained largely the
same in the past 40 years at our institution, we make
practical suggestions based on our operative experiences of
JTPGLs. The importance of pre-operative DSA cannot be
overemphasized; it ensures adequacy of venous supply on
the contralateral side, which minimizes the risk of cerebral
infarction [25]. Transposition of the facial nerve is not
essential; keeping the nerve in its bony recess is often
enough to preserve intact neural function while allowing
superior and inferior approach to the tumor (the so-called
fallopian bridge technique) [26]. Blind-sac closure of the
external ear is not necessary if no CSF fistula is seen during
the operation, but should be undertaken when a fistula is
seen or when the risk of it is high. In general, the external
auditory canal can be preserved when there is ‘‘minimal
middle ear extension and limited involvement of the car-
otid artery’’ [27]. When handling the internal jugular vein,
we recommend packing the cranial end of the sigmoid
sinus instead of ligating it and ligating the caudal end [28].
To avoid backpressure and unnecessary intraoperative
bleeding, distal occlusion of the jugular vein should be
performed just before the tumor is removed [29]. If a
tympanic PGL does not invade into the chorda tympani
nerve, the nerve should be preserved. If invasion into the
nerve is noticed, the nerve should be resected. In most
cases, the symptoms following unilateral resection of the
chorda tympani nerve (e.g. taste disturbances) are tempo-
rary and will be enbursed by the function of the con-
tralateral chorda tympani nerve. An interesting, recent
study explores taste function after chorda tympani resec-
tion further [30].
RT has shown promising local control rates and few
complications compared to surgery in the treatment of
HNPGLs [31]. RT is believed to induce an obliterative
endarteritis with resultant fibrosis; this may prevent
regrowth of the tumor and promote partial tumor involution
[32, 33]. Two patients in the current study received primary
RT and for both, no new growth in the tumor was seen at
2 years post-RT. While the first patient wanted no follow-
up, the second suffered a long-term CN XII palsy post-
RT—albeit with normal swallowing function. Patient 21
(Table 4) developed a new CN VII palsy 2 years after
secondary RT with no new growth in the tumor. In a review
by Hu and Persky, 1 % of cranial neuropathies were noted
to worsen after RT, while Powell et al. report 2 new CN
VII deficits (2/46, 4 %) post-RT [34–37]. With appropriate
dosing and modern treatment regimens RT is customarily
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well tolerated with complications mostly limited to local
irritations. Still, new CN complications remain a possibility
post-RT.
Ahmad et al. recommend extending the post-operative
follow-up for JTPGLs to at least 10 years after primary
surgery [11]. Based on our data of 40 years, multiple Fisch
Class B-D tumors showed recurrence after several years of
follow-up. In one primary B1 tumor, a recurrence was seen
after 14 years. There were no recurrences in Class A
tumors in our cohort. We thus agree with Ahmed et al. and
recommend a follow-up of at least 10 years for Class B–D
tumors. Follow-up for Class A tumors can be shorter as
long as the tumor resection has been radical.
Conclusion
In the treatment of JTPGLs, we opt for radical surgery
when complete removal of the tumor is possible. In cases
of inoperable tumors, we consider primary RT, which has
shown great potential for local tumor control. When CNs
VII–XII are in danger, our choice is function-preserving
surgery with or without adjuvant RT. With long enough
post-operative follow-up the residuals and recurrences can
be dealt with and patients maintain their maximum quality-
of-life, devoid of unnecessary CN palsies, and further
dangers of high risk surgery. Overall, the treatment of
JTPGLs in our institution has become more conservative
over the years.
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